Previous studies have indicated that SARS-CoV-2 uses angiotensin converting enzyme 2 (ACE2) as a cell entry receptor, prompting some authors to suggest that treatment with ACEI or ARB may increase the risk of severe complications associated with COVID-19 [30]. The gene discussed is ACE2; the disease is COVID-19.